Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-2,page-paged-2,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.1,vc_responsive

CLIENT NEWS

 

 

  • Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins
    www.rentschler-fill-solutions.com
  • GBA Group Pharma: LKF focuses on SARS-CoV-2 analysis: Ongoing COVID-19 testing to maintain clinical studies
    www.gba-group.com
  • APEIRON Biologics announces financing round for the further development of the COVID-19 drug APN01
    www.apeiron-biologics.com
  • Abivax SA: €36 million non-dilutive funding from Bpifrance for Abivax’ ABX464 Covid-19 program
    www.abivax.com
  • AiCuris unterstützt das Land NRW bei der COVID-19 Ausbruchsbekämpfung in Schlachtbetrieben
    www.aicuris.com
  • Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program
    www.veronapharma.com
  • Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial
    www.abivax.com
  • Abivax SA: ABX464 inhibits replication of SARS-CoV-2 (COVID-19) in reconstituted human respiratory epithelium model
    www.abivax.com
  • 4basebio AG reports first quarter 2020 financial results
    www.4basebio.com
  • CENTOGENE AG: Blaupause für die Bundesrepublik – CENTOGENE ermöglicht Coronavirus-Tests am Gymnasium Neustrelitz
    www.centogene.com